The Seattle Genetics, Inc. (SGEN) Shares Bought by the Rhumbline Advisers

Marco Green
October 23, 2017

OMCL's profit will be $7.49 million for 67.06 P/E if the $0.20 EPS becomes a reality. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. About shares traded. Level 3 Communications, Inc. (NDAQ:SGEN) has risen 75.68% since October 23, 2016 and is uptrending. It has underperformed by 1.61% the S&P500.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Thursday, July 27th. SGEN's SI was 11.62M shares in October as released by FINRA. Its up 52.92% from 280,600 shares previously. With 894,200 avg volume, 13 days are for Seattle Genetics Incorporated (NASDAQ:SGEN)'s short sellers to cover SGEN's short positions. TIAA CREF Investment Management LLC increased its stake in Seattle Genetics by 6.4% in the third quarter. During the last trade, stock's minimum price has been reached out at $259.44 while the maximum trading price moved at $264.83. Sei Investments Company sold 12,306 shares as Seattle Genetics Inc (SGEN)'s stock rose 1.68%. (NASDAQ:SGEN) rating on Tuesday, June 20. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc. (NASDAQ:SGEN) ended its day at $63.86 with the rising stream of -0.23% and its total traded volume was 1.54 million shares more than the average volume. Neuberger Berman Group LLC now owns 12,630 shares of the biotechnology company's stock worth $794,000 after purchasing an additional 59 shares during the period. 41 funds opened positions while 138 raised stakes. The correct version of this article can be read at https://weekherald.com/2017/10/23/6524-shares-in-seattle-genetics-inc-sgen-purchased-by-verition-fund-management-llc.html. BlackRock Inc. increased its stake in Seattle Genetics by 36.7% in the third quarter. The fund bought 6,524 shares of the biotechnology company's stock, valued at approximately $338,000. Neuberger Berman Group LLC raised its stake in Seattle Genetics by 0.5% during the first quarter. Advantus Management Incorporated holds 29,356 shares or 0.05% of its portfolio. Piper Jaffray Companies reiterated a "neutral" rating and issued a $48.00 price objective on shares of Seattle Genetics in a report on Tuesday, June 27th. Schwartz Counsel owns 20,000 shares. Cwm Limited Liability Company reported 0% in Seattle Genetics, Inc. Susquehanna Intl Group Llp holds 7,272 shares or 0% of its portfolio. Amalgamated National Bank has 33,195 shares. Carl Domino accumulated 0.31% or 5,200 shares. Zacks Investment Research downgraded shares of Seattle Genetics from a "buy" rating to a "hold" rating in a research note on Monday, October 16th. Therefore 50% are positive. The company was maintained on Friday, April 28 by Cann. The firm has "Outperform" rating given on Friday, July 31 by Oppenheimer. Align Technology, Inc.'s beta is 1.36 whilst the stock has an average true range (ATR) of 3.55. The firm earned "Hold" rating on Thursday, July 27 by Cowen & Co. Canaccord Genuity has "Buy" rating and $62 target. Barclays Capital initiated it with "Overweight" rating and $54 target in Tuesday, October 18 report. As per Friday, June 2, the company rating was maintained by Oppenheimer. The firm has "Outperform" rating by Macquarie Research given on Thursday, September 3.

Level 3 Communications, Inc.is a provider of a range of integrated communications services. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. (NASDAQ:SGEN) for 110,990 shares.

Sei Investments Company decreased Seattle Genetics Inc (SGEN) stake by 68.22% reported in 2017Q2 SEC filing. The company has market cap of $2.01 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It now has negative earnings. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Investors sentiment decreased to 1.3 in Q2 2017. Its up 0.23, from 1.2 in 2017Q1. It turned negative, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.03. Tributary Capital stated it has 20,200 shares. The share price was last seen -0.23% lower, reaching at $63.86 on October 20, 2017. Mondrian Invest Prtn Ltd invested in 0.11% or 87,808 shares. Cantor Fitzgerald restated a "hold" rating and set a $43.00 price target on shares of Seattle Genetics in a report on Monday, June 26th. The insider SIEGALL CLAY B sold $679,698. Greenwood Cap Associates Limited accumulated 10,986 shares. Commonwealth Equity Services invested in 6,042 shares. Massachusetts-based Trillium Asset Management has invested 0.08% in Omnicell, Inc. State Board Of Administration Of Florida Retirement Systems reported 0.02% stake. California Public Employees Retirement Systems invested in 228,600 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER